{
  "docId": "019de075-5375-74ac-b63e-223f7dcbcdee",
  "docSlug": "1e5a737805b52115da5825472ef93325",
  "documentTitle": "Hillstream BioPharma | Investor Presentation Deck | 19 slides",
  "authorId": "hillstream-biopharma",
  "authorName": "Hillstream BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 19,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a table to compare market incumbents with the company's pipeline asset, followed by a structural biology illustration.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5375-74ac-b63e-223f7dcbcdee/15",
  "deckHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee",
  "deckJsonHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee.json",
  "deckAnchorHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.72,
        "y": 0.22
      },
      "kind": "callout",
      "text": "Merck's KEYTRUDA binds 30 times more tightly than BMS's OPDIVO",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acb04ec3-a34f-4503-b051-a34b7fc9e616",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "image",
      "text": "Structural diagrams of KEYTRUDA and OPDIVO binding to PD-1",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5cdf2bc-13fa-4993-ab16-da22c9de7ba6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.45,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Knobs domains are much smaller (~4K Da) compared to large full-length PD-1 antibodies and could theoretically bind to novel epitopes of PD-1",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4189efc-aa5c-48cf-8489-ba9d4bf165d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.5,
        "y": 0.5
      },
      "kind": "source-note",
      "text": "*Disassociation Constant or the KD is a measure of how “tightly” the antibody binds its target. LOWER KD -> TIGHTER Binding",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21d2f6a0-6ab0-4a87-a4f9-53622ceddf93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.68,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Target, Company, Drug, 2022 Sales, Dissociation (KD)*; PD-1, Bristol-Myers, OPDIVO, $12.6 Billion, ~1,450 pico-Molar; PD-1, Merck, KEYTRUDA, $20.9 Billion, 50 pico-Molar; PD-1, Hillstream, HSB-1940, , Expected lower KD",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93aa26dc-fb16-45fb-94cd-1a5f9cc3c5ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.85,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "HSB-1940 May Bind More Tightly to Epitopes in PD-1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aece3a62-d69e-4807-8e1b-aeadb20ba641",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "ae53b256-2110-412c-bfbe-35270ab5a975",
      "evidence": "table/data: Target, Company, Drug, 2022 Sales, Dissociation (KD)*; seems to be a 2x2 table but not clearly stated",
      "confidence": 0.5
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "5c710c82-42e0-4f70-aab4-81a64792fd2d",
      "evidence": "table/data: Target, Company, Drug, 2022 Sales, Dissociation (KD)*",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}